上皮性卵巢癌患者主流胚系基因检测提高检测率并降低医疗支付方视角的遗传相关医疗成本
该研究评估实施主流胚系基因检测路径对上皮性卵巢癌新诊断患者接受基因检测比例及遗传相关医疗成本的影响。
要点
- 实施主流基因检测路径后,新诊断上皮性卵巢癌患者6个月内基因检测提供率从56%升至70%(p=0.005)。
- 主流基因检测可提高检测提供率并降低医疗支付方视角的遗传相关成本。
核心结论
- 主流基因检测使新诊断上皮性卵巢癌患者接受胚系基因检测的比例显著提高,并显著降低每例患者的遗传相关医疗成本。
研究设计与样本
- 研究分析实施主流基因检测路径前(2016年3月至2017年9月)和后(2018年4月至2019年12月)所有新诊断上皮性卵巢癌患者的病历资料。
- 研究梳理了遗传咨询和检测的可能诊疗路径及其相关成本,基于诊断相关组(DRG)融资方法从医疗支付方视角计算遗传相关医疗成本。
主要发现
- 实施主流基因检测路径后6个月内,基因检测提供率从56%升至70%(p=0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Germline genetic testing is increasingly offered to patients with epithelial ovarian cancer by non-genetic healthcare professionals, so called mainstream genetic testing. The aim of this study was to evaluate the effect of implementing a mainstream genetic testing pathway on the percentage of newly diagnosed patients with epithelial ovarian cancer to whom genetic testing was offered and the genetics-related healthcare costs. METHODS: The possible care pathways for genetic counseling and testing and their associated costs were mapped. Patient files from all newly diagnosed patients with epithelial ovarian cancer before (March 2016 - September 2017) and after (April 2018 - December 2019) implementing our mainstream genetic testing pathway were analyzed. Based on this analysis, the percentage of newly diagnosed patients to whom genetic testing was offered was assessed and genetics-related healthcare costs were calculated using a healthcare payer perspective based on a Diagnosis-Related Group financing approach. RESULTS: Within six months after diagnosis, genetic testing was offered to 56% of patients before and to 70% of patients after implementation of our mainstream genetic testing pathway (p = 0.005). Genetics-related healthcare costs decreased from €3.511,29 per patient before implementation to €2.418,41 per patient after implementation of our mainstream genetic testing pathway (31% reduction, p = 0.000). CONCLUSION: This study shows that mainstream genetic testing leads to a significantly higher proportion of newly diagnosed patients with epithelial ovarian cancer being offered germline genetic testing. In addition, it significantly reduces genetics-related healthcare costs per patient.
引用
- Bokkers K, Frederix GWJ, Velthuizen ME, et al. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective. Gynecol Oncol. 2022. PMID: 36031452. doi:10.1016/j.ygyno.2022.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。